Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Awakn Life Sciences Corp (OP: AWKNF ) 0.0800 +0.0120 (+17.65%) Streaming Delayed Price Updated: 10:09 AM EDT, Oct 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 11,048 Open 0.0550 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 0.0680 Today's Range 0.0550 - 0.0800 52wk Range 0.0422 - 0.2600 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Investors Back Awakn's Psychedelic Therapies, As Company Doubles Private Placement To $2M September 18, 2024 Awakn Life Sciences expands its private placement to $2 million, closing the fourth tranche with $394,286 raised to accelerate research into addiction treatments. Via Benzinga Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More April 17, 2024 Via Benzinga Performance YTD -27.60% -27.60% 1 Month -23.30% -23.30% 3 Month +6.67% +6.67% 6 Month -15.79% -15.79% 1 Year -57.42% -57.42% More News Read More Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More February 15, 2024 Via Benzinga Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More January 26, 2024 Via Benzinga Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More December 27, 2023 Via Benzinga Awakn Life Sciences Enters Into Global Licensing Agreement For Sublingual Delivery Formulation December 21, 2023 Via Benzinga Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More November 24, 2023 Via Benzinga Topics Cannabis Exposures Cannabis UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center November 15, 2023 Via Benzinga U.K.'s Prof. David Nutt Ranked World's Top Psychopharmacologist: More On His Contributions & Advocacy October 15, 2023 Via Benzinga Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More September 11, 2023 Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Awakn Life Sciences Submits CTA For Phase III Alcohol Use Disorder Clinical Trial September 06, 2023 Via Benzinga Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More August 14, 2023 Via Benzinga Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More August 03, 2023 Via Benzinga Awakn Life Sciences Becomes Pure R&D Biotech After Sale Of Norway Clinics August 01, 2023 Via Benzinga Awakn Life Sciences On Track With Phase 3 Trial To Research Substance Use Disorder July 26, 2023 Via Benzinga Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More July 11, 2023 Via Benzinga Awakn Life Sciences Sells London Clinics Business, Hopes To Divest Norwegian Unit Next July 05, 2023 Via Benzinga Awakn Life Sciences Announces Closing Of Second Tranche And Upsizing Of Previous Private Placement June 15, 2023 Via Benzinga Awakn To Focus On R&D Of Addiction Therapies, Moves Away From Ketamine Treatment For Alcoholism June 12, 2023 Via Benzinga Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More May 01, 2023 Via Benzinga Awakn's Q4 2023 And Annual Financials, +500% YoY Revenue Increase Following Network Expansion April 28, 2023 Via Benzinga Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More April 24, 2023 Via Benzinga Severe Alcohol Use Disorder Patients Will Try Ketamine Therapy At Awakn's New Phase 3 Study April 19, 2023 Via Benzinga EXCLUSIVE: MDMA Therapy Experts Debate Upcoming Approval And Psychedelic Market Opps April 19, 2023 Via Benzinga Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More April 17, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.